mots-c
METABOLIC · MITOCHONDRIAL-DERIVED PEPTIDE · 16 AA · PRECLINICAL
MOTS-c is a 16-amino-acid mitochondrial-derived peptide that activates AMPK and shows metabolic and exercise-mimetic effects in rodent models. Human evidence is essentially absent: the only clinical data come from a phase 1a/1b trial of the analogue CB4211 in 88 subjects that met safety endpoints but showed liver fat reduction no better than placebo, and the developing company subsequently dissolved.
// our evidence grade — unedited
MOTS-c has a coherent preclinical mechanism and one small phase 1a/1b safety trial of an analogue, but no randomised efficacy trial of MOTS-c itself in humans, a failed liver-fat endpoint for its lead analogue, a discontinued development programme and an FDA compounding restriction.
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) |
| cas | 1627580-64-6 |
| formula | C101H152N28O22S2 |
| molar mass | 2174.6 g/mol |
| purity | ≥ 99% HPLC |
| form | lyophilised powder, sealed vial |
| storage | Lyophilised material is typically stored at −20 °C in desiccated, light-protected vials, with vendor stability data commonly citing up to 3 years; stock solutions are generally held at −80 °C for up to about a year or −20 °C for roughly a month. |
| solubility | Readily soluble in water (approximately 40 mg/mL) and in DMSO (approximately 100 mg/mL); insoluble in ethanol. |
| sequence | MRWQEMGYIFYPRKLR |
// select size
crypto payment · research use only · not for human consumption
// others in Metabolic